Overactive Bladder - Results from #140

A Discrete Mathematics Approach for Understanding Risk Factors in Overactive Bladder Treatment. March 3, 2024

Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH). March 3, 2024

Job strain, occupation, and bladder health among women March 1, 2024

Need for Public Health Messaging Related to Bladder Health from Adolescence to Advanced Age. March 1, 2024

A positive association between food insecurity and the prevalence of overactive bladder in U.S. adults. February 25, 2024

Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator. February 25, 2024

The Impact of Extracorporeal Magnetic Stimulation as Addition to Mirabegron in Overactive Bladder Treatment in Women: A Single-Centre Randomized Sham-Controlled Study. February 18, 2024

Prevalence of overactive bladder among overweight and obese women: A prospective cross-sectional cohort study. February 18, 2024

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder. February 11, 2024

Microstructural white matter abnormalities in overactive bladder syndrome evaluation with diffusion kurtosis imaging tract-based spatial statistics analysis. February 11, 2024

Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection. February 11, 2024

Exploring lifelong overactive bladder: Transitions, evidence, and clinical implications; A modified Delphi process. February 4, 2024

Safety and efficacy of an α1 -blocker plus mirabegron compared with an α1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis February 4, 2024

Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment. February 4, 2024

Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. January 28, 2024

What is the best first choice oral drug therapy for OAB? January 28, 2024

Quality of Life in Female Patients with Overactive Bladder after Botulinum Toxin Treatment. January 28, 2024

Anatomical location and number of injection sites of intravesical OnabotulinumtoxinA for females with refractory idiopathic overactive bladder: A scoping review. January 21, 2024

Clinical tools for evaluating the severity of overactive bladder: A systematic review of psychometric properties. January 21, 2024

Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA Registry. January 21, 2024

Page 8 of 122